Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Biomarker Predicts Response to Therapy in Patients with a Rare Form of Metastatic Colorectal Cancer

By LabMedica International staff writers
Posted on 29 Sep 2022

Cancer researchers have identified a biomarker that predicts response of patients with microsatellite stable BRAF V600E metastatic colorectal cancer (MSS mCRC) to treatment with combined anti-BRAF/EGFR therapy. More...

Microsatellites are repeated sequences of DNA. These sequences can be made of units of one to six base pairs in length that are repeated and reside adjacent to each other in the genome. Although the length of microsatellites can vary from person to person and contributes to the individual DNA "fingerprint", each individual has microsatellites of a set length.

Mutations in BRAFV600E occur in around 10% of mCRC, and while relatively rare, they associate with a poor prognosis. Since a large fraction of mCRC patients do not respond to the recently approved combined anti-BRAF/EGFR therapy, there is an urgent need to identify the molecular determinants of treatment response.

In this regard, investigators at Vall d'Hebron Institute of Oncology (Barcelona, Spain) used whole-exome sequencing and targeted next generation sequencing (NGS) to analyze a discovery cohort of patients with mCRC(BRAF-V600E) treated with anti-BRAF/EGFR therapy. In addition, a control cohort of patients with mCRC(BRAF-V600E) receiving standard chemotherapies and anti-angiogenic agents (and not exposed to anti-BRAF) was evaluated. Data obtained from the molecular analyses were integrated with clinical correlates of response and survival.

Results revealed that inactivating mutations in RNF43, a negative regulator of the WNT signaling pathway, predicted improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. The response rate among patients with a BRAFV600E MSS mCRC carrying a RNF43 mutation reached 72.7%, and only 30.8% in those without the mutation. In patients with tumors harboring the RNF43 mutation, median disease-free progression was 10.1 months versus 4.1 months and overall survival in the former was 13.6 months compared to seven months in the latter.

The investigators concluded that patients with MSS-mCRC(BRAF-V600E) tumors harboring loss-of-function mutations in RNF43 responded favorably to combined anti-BRAF/EGFR therapy, whereas those with functional RNF43 derived limited benefit from this treatment.

"We performed extensive genomic analysis of over 20,000 genes. In total, we analyzed data from 166 patients which represents a significant number considering the rarity of this tumor subtype that accounts for around 10% of all colorectal cancers," said senior author Dr. Rodrigo A. Toledo, a translational investigator at Vall d'Hebron Institute of Oncology. "Our data point to RNF43 as a potential stratification biomarker that could help steer treatment decision making as well as define the optimal sequence of treatment in patients with microsatellite stable, BRAF V600E- mutant metastatic colorectal cancer. As importantly, it could also help to identify those patients for whom alternative treatment options are very much needed."

The study was published in the September 12, 2022, online edition of the journal Nature Medicine.

Related Links:
Vall d'Hebron Institute of Oncology 


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.